Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Financing led by Bay City Capital with participation from New Enterprise Associates (NEA) and Merlin Nexus
WALTHAM, Mass.--(BUSINESS WIRE)-- Interleukin Genetics, Inc. (OTCQB: ILIU) will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Company's first quarter results.
As reported previously this week, Interleukin has raised $12 million through a private placement of its securities. The financing was comprised of new investors led by Bay City Capital with participation from NEA and Merlin Nexus. Dayton Misfeldt and Lionel Carnot, Investment Partners at Bay City Capital, have joined Interleukin's Board of Directors.
"We are excited to support Interleukin Genetics in the commercialization of its PST® genetic test for periodontal disease susceptibility," said Dayton Misfeldt. "Important new scientific evidence emerging on the value of the IL-1 genetic test for periodontitis risk should enable Interleukin to widely distribute the PST test and its personalized health approach to dentistry which will assist dentists in providing the care their patients need," added Lionel Carnot.
Interleukin Genetics intends to use the net proceeds from the private placement primarily to move its currently validated molecular diagnostic tests, most immediately the test for predicting periodontitis progression and severity(PST), into broad commercialization.
"We are very pleased to have the support of outstanding life science investors such as Bay City Capital, NEA, and Merlin," said Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics. "The new financing will allow us to rapidly move to commercialize the emerging evidence that shows the value of PST in guiding better oral health and the optimal use of preventive resources for adult periodontitis, one of the most common chronic diseases of aging."
Conference Call Information
Interleukin will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Company's first quarter results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.'s Website at http://www.ilgenetics.com.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® and PST® brands. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements, including statements relating to commercialization of Interleukin's PST test. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Interleukin Annual Report on Form 10-K for the year ended December 31, 2012 and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Media:
Interleukin Genetics, Inc.
Jennifer Violette, 781-398-0710
Public Relations
jviolette@ilgenetics.com
or
Investors:
Interleukin Genetics, Inc.
Eliot Lurier, 781-398-0700, ext. 1204
Chief Financial Officer
elurier@ilgenetics.com
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS:
The article Interleukin Genetics to Discuss Corporate Update and First Quarter Results originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
